Microbial mechanism of biologics in the prevention and treatment of inflammatory bowel disease

Microbial mechanism of infliximab in preventing postoperative recurrence of Crohn's disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000033770

Enrollment

Unknown

Registered

2020-06-11

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

IFX treatment group vs non IFX treatment group:nil

recurrence group vs. remission group:nil

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. 18-70 years old patients diagnosed with CD patients; 2. Patients require ileocolonic resection owing to CD-related complications or failure of mediacal treatment.

Exclusion criteria

Exclusion criteria: 1. CD Patients require perianal surgical intervention, upper intestinal tract surgery, stomy or abscess drainage. 2. Patients who received antibiotics during the previous three months. 3. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Endoscopic recurrence or remission;Incidence of adverse events;	—

Countries

China

Contacts

Public ContactXiaolei Wang

Shanghai Tenth People's Hospital

wangxiaolei@tongji.edu.cn+86 13817267967

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026